The short answer
Kava may add to doxylamine-related drowsiness or impaired alertness. Review the exact product and other sedating medicines before adding it; this combination’s risk has not been measured directly.
What this answer covers
Piper methysticum preparations; extract, beverage and dose vary.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- doxylamine
The medicine can affect alertness
Ask doctor/pharmacist before other sedatives or sleep aids; do not drive; use only at bedtime with a full night available. These medication warnings do not supply a supplement-specific adverse-event rate.
What the supplement evidence shows
A small driving-simulator crossover found no significant impairment after one medicinal kava dose. Kava and oxazepam were taken in separate sessions. That null result does not establish safety of simultaneous co-use or stronger extracts.
Keep the preparation and outcome clear
Dose, formulation and other ingredients matter. No exact-pair trial identified here established how much impairment would increase, and a negative result for one product alone does not prove the combination safe. OTC doxylamine sleep tablets and the delayed-release doxylamine/pyridoxine product for pregnancy nausea have different purposes and schedules. Their doxylamine effects are relevant, but the formulations are not interchangeable.
Review co-use and daily activities
Discuss the product with the prescriber or pharmacist before adding it. Avoid driving while drowsy or dizzy. No exact protective spacing interval was established, and a supplement should not be used to counteract medication impairment.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-alertness precaution from medication-specific effects and supplement guidance; direct pair harm, respiratory depression rate and protective spacing not established.
- Exact scope
- Piper methysticum preparations; extract, beverage and dose vary. with Oral doxylamine succinate sleep-aid tablets; delayed-release doxylamine/pyridoxine pregnancy product considered separately.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed doxylamine
Ask doctor/pharmacist before other sedatives or sleep aids; do not drive; use only at bedtime with a full night available.
How this applies: Exact doxylamine RxCUI 3642 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed doxylamine
Delayed-release doxylamine succinate/pyridoxine hydrochloride pregnancy product: somnolence due to doxylamine; CNS-depressant co-use not recommended, anticholinergic precautions.
How this applies: Exact doxylamine RxCUI 3642 IN, with stated salt/formulation/route bridge.
Same active ingredient, different formulation or combination. Product-specific results cannot be transferred as identical exposure.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Advises against combining kava with other sedating substances. Products vary and separate liver-injury concerns are described.
How this applies: Interpreted for doxylamine only within the stated exact preparation and endpoint limits.
No exact doxylamine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-two adults in a crossover driving-simulator trial.
Kava did not significantly impair driving compared with placebo; oxazepam impaired selected measures.
How this applies: Interpreted for doxylamine only within the stated exact preparation and endpoint limits.
No exact doxylamine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact doxylamine article with formulation-specific evidence and uncertainty. |
Article revision: 74c1634dff9ed84c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.